Listen on the go
CORRECT!
Next question
touchINFECTIOUS DISEASES touchINFECTIOUS DISEASES
HIV, Viral Infections

Larry Corey, HIVR4P 2021: The AMP Study – VRC01 Antibody Prevention of HIV

Share this Video
Copy Link
Published Online: Mar 23rd 2021

touchINFECTIOUS DISEASES caught up with Larry Corey (Fred Hutchinson Cancer Research Center, Seattle, WA, US) to discuss VRC01 antibody prevention of HIV, and results from the AMP study.

The abstract entitled: ‘VRC01 antibody prevention of HIV’ (HY01.01LB) was presented at the HIVR4P Virtual Conference 2021, 27 January 2021.

Questions:

  1. What is the rationale for the use of the VRC01 antibody in the prevention of HIV?
  2. What are the challenges in the use of broadly neutralizing antibodies in this indication, and how have they been overcome?
  3. How does VRC01 prevention efficacy vary with HIV-1 envelope amino acid sequence features?
  4. What is the status of research into other broadly neutralizing antibodies in the prevention of HIV?

Disclosures: Larry Corey has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of HIVR4P Virtual Conference 2021.

Related Videos In Viral Infections
HIV, Viral Infections
Developed by Touch
Antiretroviral management of HIV in clinical practice: integration of the latest data
Eric Daar Watch Time: 6 mins

Learn about the integration of the latest data in antiretroviral management of HIV, challenges clinicians may face when adopting new strategies and updates from the Conference of Retroviruses and Opportunistic Infections (CROI) 2024 are reported here by Dr Eric Daar, Division of HIV Medicine, Harbor-UCLA Medical Center, Atlanta, GA, USA.

HIV, Viral Infections
Developed by Touch
Antiretroviral therapy updates at CROI 2024: emerging treatment strategies in HIV
Eric Daar Watch Time: 8 mins

Antiretroviral therapy (ART) effectively manages HIV by suppressing viral replication. It's crucial for healthcare professionals (HCPs) to keep abreast of ART updates for optimal patient care. Dr. Eric Daar, Harbor-UCLA Medical Center, reports on CROI 2024, underscoring the efficacy of long-acting injectable (LAI) therapies in trials like CARES, MOCHA, and LATITUDE. The findings support LAI therapy's potential for global HIV treatment programs, including in resource-limited settings like sub-Saharan Africa.

Viral Infections
Developed by Touch
DANFLU-1: post-hoc analysis of high-dose quadrivalent influenza vaccines: Niklas Dyrby Johansen, ECCMID 2023
Watch Time: 5 mins

DANFLU-1 was an open-label, active-controlled, individually randomized trial conducted in Denmark during the 2021/2022 northern hemisphere influenza season. Dr Niklas Dyrby Johansen (University of Copenhagen Copenhagen, Denmark) discusses the post-hoc analysis from DANFLU-1 which investigated the effects of high-dose quadrivalent influenza vaccine (QIV-HD) vs standard-dose quadrivalent influenza vaccine (QIV-SD). The abstract ‘Relative effectiveness of high-dose […]

Trending In Viral Infections:

Antiretroviral management of HIV in clinical practice: integration of the latest data
HIV, Viral Infections
    • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72